These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

61 related articles for article (PubMed ID: 15564744)

  • 1. High sustained virologic response rate after interferon monotherapy in Japanese hepatitis C patients with a low HCV RNA titer and/or HCV genotype 2. A prospective study.
    Yokosuka O; Iwama S; Suzuki N; Takashi M; Hirai Y; Uchiumi K; Kimura M; Gotou N; Hino S; Hayasaka A; Kanda T; Kawai S; Fukai K; Imazeki F; Saisho H
    Intervirology; 2004; 47(6):328-34. PubMed ID: 15564744
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Discordance between serum alanine aminotransferase (ALT) and virologic response to IFN-alpha2b in chronic hepatitis C patients with high and low pretreatment serum hepatitis C virus RNA titers.
    Blatt LM; Tong MJ; McHutchison JG; Russell J; Schmid P; Conrad A
    J Interferon Cytokine Res; 1998 Feb; 18(2):75-80. PubMed ID: 9506457
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Twenty-four weeks of interferon alpha-2b in combination with ribavirin for Japanese hepatitis C patients: sufficient treatment period for patients with genotype 2 but not for patients with genotype 1.
    Fujiwara K; Yokosuka O; Komine F; Moriyama M; Kato N; Yoshida H; Tanaka N; Imazeki F; Shiratori Y; Arakawa Y; Omata M;
    Liver Int; 2006 Jun; 26(5):520-8. PubMed ID: 16761995
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combined interferon alpha2b and cyclosporin A in the treatment of chronic hepatitis C: controlled trial.
    Inoue K; Sekiyama K; Yamada M; Watanabe T; Yasuda H; Yoshiba M
    J Gastroenterol; 2003; 38(6):567-72. PubMed ID: 12825133
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lymphoblastoid interferon alfa-n1 improves the long-term response to a 6-month course of treatment in chronic hepatitis C compared with recombinant interferon alfa-2b: results of an international randomized controlled trial. Clinical Advisory Group for the Hepatitis C Comparative Study.
    Farrell GC; Bacon BR; Goldin RD
    Hepatology; 1998 Apr; 27(4):1121-7. PubMed ID: 9537453
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of ribavirin in genotype 1 patients with hepatitis C responding to pegylated interferon alfa-2a plus ribavirin.
    Bronowicki JP; Ouzan D; Asselah T; Desmorat H; Zarski JP; Foucher J; Bourlière M; Renou C; Tran A; Melin P; Hézode C; Chevalier M; Bouvier-Alias M; Chevaliez S; Montestruc F; Lonjon-Domanec I; Pawlotsky JM
    Gastroenterology; 2006 Oct; 131(4):1040-8. PubMed ID: 17030174
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Early HCV RNA changes in patients with chronic hepatitis C treated with peginterferon alfa 2b and ribavirin.
    Gallegos-Orozco JF; Fuentes AP; Olivera-Martinez MA; Gutiérrez-Reyes G; Cortina D; Oregel JA; Pérez-Pruna C; Sixtos MS; Cruz-Castellanos S; Soto-Ramírez LE; Rodríguez-Díaz R; Fuentes-Romero L; Gutiérrez-Ruiz MC; Kershenobich D
    Rev Invest Clin; 2003; 55(2):138-42. PubMed ID: 12827916
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The efficacy of 24-week interferon monotherapy for type C liver cirrhosis in Japanese patients with genotype 1b and low virus load.
    Arase Y; Suzuki F; Sezaki H; Kawamura Y; Suzuki Y; Kobayashi M; Akuta N; Hosaka T; Yatsuji H; Hirakawa M; Kobayashi M; Ikeda K; Kumada H
    Intervirology; 2008; 51(4):265-9. PubMed ID: 18841028
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of chronic hepatitis C in patients who failed interferon monotherapy: effects of higher doses of interferon and ribavirin combination therapy. The Virginia Cooperative Hepatitis Treatment Group.
    Shiffman ML; Hofmann CM; Gabbay J; Luketic VA; Sterling RK; Sanyal AJ; Contos MJ; Ryan MJ; Yoshida C; Rustgi V
    Am J Gastroenterol; 2000 Oct; 95(10):2928-35. PubMed ID: 11051370
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The efficacy of pegylated interferon alpha 2a or 2b plus ribavirin in chronic hepatitis C patients.
    Yenice N; Mehtap O; Gümrah M; Arican N
    Turk J Gastroenterol; 2006 Jun; 17(2):94-8. PubMed ID: 16830289
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Peginterferon Alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients.
    Torriani FJ; Rodriguez-Torres M; Rockstroh JK; Lissen E; Gonzalez-García J; Lazzarin A; Carosi G; Sasadeusz J; Katlama C; Montaner J; Sette H; Passe S; De Pamphilis J; Duff F; Schrenk UM; Dieterich DT;
    N Engl J Med; 2004 Jul; 351(5):438-50. PubMed ID: 15282351
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prolonged negative HCV-RNA status led to a good outcome in chronic hepatitis C patients with genotype 1b and super-high viral load.
    Kohno H; Aimitsu S; Kitamoto M; Aisaka Y; Kawakami H; Chayama K
    Intervirology; 2006; 49(6):362-9. PubMed ID: 16926549
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Peginterferon alpha-2a (40 KD) plus ribavirin for the treatment of chronic hepatitis C in Japanese patients.
    Kuboki M; Iino S; Okuno T; Omata M; Kiyosawa K; Kumada H; Hayashi N; Sakai T
    J Gastroenterol Hepatol; 2007 May; 22(5):645-52. PubMed ID: 17444850
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pegylated interferon alfa-2b vs standard interferon alfa-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients: a randomized controlled trial.
    Carrat F; Bani-Sadr F; Pol S; Rosenthal E; Lunel-Fabiani F; Benzekri A; Morand P; Goujard C; Pialoux G; Piroth L; Salmon-Céron D; Degott C; Cacoub P; Perronne C;
    JAMA; 2004 Dec; 292(23):2839-48. PubMed ID: 15598915
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Genotype does not affect pattern of HCV RNA decrease among responders during interferon treatment of chronic hepatitis C. Consensus Interferon Study Group.
    Keeffe EB; Dusheiko GM; Tong MJ; Hollinger FB; Heathcote EJ; McHutchison J; Albert D
    Cytokines Cell Mol Ther; 1999 Dec; 5(4):211-6. PubMed ID: 10850385
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chronic hepatitis C. Genotypes and response to anti-viral therapy among Saudi patients.
    Al-Traif I; Handoo FA; Al-Jumah A; Al-Nasser M
    Saudi Med J; 2004 Dec; 25(12):1935-8. PubMed ID: 15711670
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Up-regulation of IL-18 by interferon alpha-2b/ribavirin combination therapy induces an anti-viral effect in patients with chronic hepatitis C.
    Murata K; Yamamoto N; Kawakita T; Saito Y; Yamanaka Y; Sugimoto K; Shiraki K; Nakano T; Tameda Y
    Hepatogastroenterology; 2005; 52(62):547-51. PubMed ID: 15816475
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pegylated interferon alpha-2b plus ribavirin in patients with genotype 4 chronic hepatitis C: The role of rapid and early virologic response.
    Kamal SM; El Kamary SS; Shardell MD; Hashem M; Ahmed IN; Muhammadi M; Sayed K; Moustafa A; Hakem SA; Ibrahiem A; Moniem M; Mansour H; Abdelaziz M
    Hepatology; 2007 Dec; 46(6):1732-40. PubMed ID: 17943989
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Utility of week-4 viral response to tailor treatment duration in hepatitis C virus genotype 3/HIV co-infected patients.
    Crespo M; Esteban JI; Ribera E; Falco V; Sauleda S; Buti M; Esteban R; Guardia J; Ocaña I; Pahissa A
    AIDS; 2007 Feb; 21(4):477-81. PubMed ID: 17301566
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Peginterferon-alpha-2a (40KD) and ribavirin for 16 or 24 weeks in patients with genotype 2 or 3 chronic hepatitis C.
    von Wagner M; Huber M; Berg T; Hinrichsen H; Rasenack J; Heintges T; Bergk A; Bernsmeier C; Häussinger D; Herrmann E; Zeuzem S
    Gastroenterology; 2005 Aug; 129(2):522-7. PubMed ID: 16083709
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.